The Other Press, February 19, 1987

<p>Energy profile (in kcal.mol^-1) of face-on path for Erlotinib bioactivation by the Cpd I model of CYP3A4 and 1A2 in the gas and solvent phases.</p

Additional file 5: Table S3. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

PCR Primers of ER group genes and reference genes. (DOC 32 kb

Additional file 3: Table S2. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Genes and probe sets used to characterize subgroups within ER–/PgR+/HER2– phenotype. (DOC 40 kb

Additional file 1: Figure S1. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

The study flowchart diagram. FDUSCC, Fudan University Shanghai Cancer Center; NCT, Neoadjuvant chemotherapy; SEER, Surveillance, Epidemiology and End Results program. (PPTX 111 kb

Additional file 8: Table S5. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Survival benefit from adjuvant endocrine therapy in 55 out of the 64 ER–/PgR+/HER2– cases. (DOC 30 kb

Kaplan–Meier estimates of breast cancer-specific survival and overall survival according to different treatments.

<p><b>A: Breast cancer specific survival, B: Overall survival.</b> The table below lists the results of pairwise comparisons of breast cancer-specific survival and overall survival between different treatment groups.</p

Cox proportional hazard regression model of Breast Cancer-Specific Survival comparing reconstruction method to mastectomy alone stratified by family income.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082807#pone-0082807-t002" target="_blank">Table 2</a>.^a Adjusted by Cox proportional hazards models including all factors, as categorized in </p

Cox proportional hazard regression model of Overall Survival.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082807#pone-0082807-t003" target="_blank">Table 3</a>.^a Adjusted by Cox proportional hazards models including all factors, as categorized in </p><p>^b Including American Indian/AK Native, Asian/Pacific Islander.</p><p>^c Including divorced, widowed, single (never married),separated.</p><p>% of individuals having over a 12th grade education level; Low indicates a county with less than 78.0% (including 78.0%) of individuals having over a 12th grade education level. (78.0% is the median of all county education data studied).^d High indicates a county with greater than 78.0</p><p>^e Grade are coded as followings: Well differentiated; Grade I; Moderately differentiated; Grade II; Poorly differentiated; Grade III; Unknown.</p><p>^f ER: Estrogen Receptor; PR: Progesterone Receptor.</p

Demographic and tumor characteristics of the study sample.

<p>^a P value of Chi-square test comparing the mastectomy only and the pooled reconstruction groups.</p><p>^b P value of Chi-square test comparing the autologous only and implant only groups.</p><p>^c Including American Indian/AK Native, Asian/Pacific Islander.</p><p>^d Including divorced, widowed, single (never married),separated.</p><p>% of individuals having over a 12th grade education level; Low indicates a county with less than 78.0% (including 78.0%) of individuals having over a 12th grade education level. (78.0% is the median of all county education data studied).^e High indicates a county with greater than 78.0</p><p>^f Grade are coded as followings: Well differentiated; Grade I; Moderately differentiated; Grade II; Poorly differentiated; Grade III; Unknown.</p><p>^g ER: Estrogen Receptor; PR: Progesterone Receptor.</p

Flow Diagram of Inclusion Criteria and Exclusion Criteria.

<p>The inclusion criteria are presented as follows: female sex, between 20–79 years at age of diagnosis, diagnosed as invasive breast cancer between 1990 and 2009, AJCC stages I to III and known radiotherapy status (599,548 patients). 93,954 patients diagnosed before 1990 were excluded as a result of unavailable hormone receptor data, while 39,179 patients diagnosed after 2009 were also excluded due to inadequate follow-up time. Besides, 68 patients with bilateral cases or unknown laterality were excluded. Regarding the primary tumor site, tumors located in the four quadrants and central portion were included, and tumors located on the nipple (2,398 patients), axillary tail (3,351 patients), overlapping region (97,205 patients) and not otherwise specified (57,950 patients) were excluded to avoid selection bias. So, 305,443 patients were included in this study eventually.</p